PT  - JOURNAL ARTICLE
AU  - Durstenfeld, Matthew S.
AU  - Peluso, Michael J.
AU  - Kelly, J. Daniel
AU  - Win, Sithu
AU  - Swaminathan, Shreya
AU  - Li, Danny
AU  - Arechiga, Victor M.
AU  - Zepeda, Victor
AU  - Sun, Kaiwen
AU  - Shao, Shirley
AU  - Hill, Christopher
AU  - Arreguin, Mireya I.
AU  - Lu, Scott
AU  - Hoh, Rebecca
AU  - Tai, Viva
AU  - Chenna, Ahmed
AU  - Yee, Brandon C.
AU  - Winslow, John W.
AU  - Petropoulos, Christos J.
AU  - Kornak, John
AU  - Henrich, Timothy J.
AU  - Martin, Jeffrey N.
AU  - Deeks, Steven G.
AU  - Hsue, Priscilla Y.
TI  - Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection
AID  - 10.1101/2021.11.24.21266834
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.24.21266834
4099  - http://medrxiv.org/content/early/2021/11/26/2021.11.24.21266834.short
4100  - http://medrxiv.org/content/early/2021/11/26/2021.11.24.21266834.full
AB  - BACKGROUND Shortness of breath, chest pain, and palpitations occur as post-acute sequelae of COVID-19 (PASC), but whether symptoms are associated with echocardiographic abnormalities, cardiac biomarkers, or markers of systemic inflammation remains unknown.METHODS In a cross-sectional analysis, we assessed symptoms, performed echocardiograms, and measured biomarkers among adults >8 weeks after PCR-confirmed SARS-CoV-2 infection. We modeled associations between symptoms and baseline characteristics, echocardiographic findings, and biomarkers using logistic regression.RESULTS We enrolled 102 participants at a median 7.2 months (IQR 4.1-9.1) following COVID-19 onset; 47 individuals reported dyspnea, chest pain, or palpitations. Median age was 52 years (range 24-86) and 41% were women. Female sex (OR 2.55, 95%CI 1.13-5.74) and hospitalization during acute infection (OR 3.25, 95%CI 1.08-9.82) were associated with symptoms. IgG antibody to SARS-CoV-2 receptor binding domain (OR 1.38 per doubling, 95%CI 1.38-1.84) and high-sensitivity C-reactive protein (OR 1.31 per doubling, 95%CI 1.00-1.71) were associated with symptoms. Regarding echocardiographic findings, 4/47 (9%) with symptoms had pericardial effusions compared to 0/55 without symptoms (p=0.038); those with pericardial effusions had a median 4 symptoms compared to 1 without (p<0.001). There was no strong evidence for a relationship between symptoms and echocardiographic functional parameters (including left ventricular ejection fraction and strain, right ventricular strain, pulmonary artery pressure) or high-sensitivity troponin, NT-pro-BNP, interleukin-10, interferon-gamma, or tumor necrosis factor-alpha.CONCLUSIONS Among adults in the post-acute phase of SARS-CoV-2 infection, SARS-CoV-2 RBD antibodies, markers of inflammation and, possibly, pericardial effusions are associated with cardiopulmonary symptoms. Investigation into inflammation as a mechanism underlying PASC is warranted.FUNDING This work was supported by the UCSF Division of Cardiology at Zuckerberg San Francisco General, and the National Institutes of Health/National Heart Lung Blood Institute and National Institute of Allergy and Infectious Diseases. MSD is supported by NIH 5K12HL143961. MJP is supported on NIH T32 AI60530-12. JDK is supported by NIH K23AI135037. TJH is supported by NIH/NIAID 3R01A1141003-03S1. PYH is supported by NIH/NAID 2K24AI112393-06. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.Competing Interest StatementAC, BCY, JWW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCorp. PYH has received modest honoraria from Gilead and Merck and research grant from Novartis unrelated to the submitted work. All other authors report no conflicts.Funding StatementFUNDING This work was supported by the UCSF Division of Cardiology at Zuckerberg San Francisco General, and the National Institutes of Health/National Heart Lung Blood Institute and National Institute of Allergy and Infectious Diseases. MSD is supported by NIH 5K12HL143961. MJP is supported on NIH T32 AI60530-12. JDK is supported by NIH K23AI135037. TJH is supported by NIH/NIAID 3R01A1141003-03S1. PYH is supported by NIH/NAID 2K24AI112393-06. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval was granted by the University of California, San Francisco.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.TTEtransthoracic echocardiogramPASC(post-acute sequelae of COVID-19)hsCRPhigh sensitivity c reactive proteinLIINCLong-term Impact of Infection with Novel CoronavirusHIVhuman immunodeficiencyNT-pro-BNPN-terminal prohormone b-type natriuretic proteinILinterleukinTAPSEtricuspid annular plane systolic excursionPOTSpostural orthostatic tachycardia syndromeLVleft ventricleRVright ventricle